Ligand Pharmaceuticals Hits New 52-Week High of $258.06, Up 220%

Ligand Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 258.06 on June 11, 2026. This achievement underscores the company's robust performance in the pharmaceuticals and biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 3,898 million. Over the past year, Ligand Pharmaceuticals has demonstrated impressive growth, with a remarkable 220.09% increase in stock price compared to the S&P 500's 22.78% performance. The company has reported strong financial metrics, including a net profit of USD 36.68 million, which has grown by 157.25% in the last quarter. Additionally, Ligand's operating cash flow reached a peak of USD 123.57 million, reflecting its solid financial health. With a price-to-book ratio of 3.83 and a return on equity of 5.61%, Ligand Pharmaceuticals showcases an attractive valuation. The company is also net-debt free, further enhancing its financial stability. High institutional holdings at 100% indicate strong confidence in the company's fundamentals, contributing to its market-beating performance over both the long and short term.